HCM: who should get an implantable cardioverter defibrillator in Europe and the US in 2022?

Back

EHRA Premium Access

HCM: who should get an implantable cardioverter defibrillator in Europe and the US in 2022?

Session: Risk calculators in arrhythmias: are they useful?

Topic: Genetic Aspects of Arrhythmias

Speaker: Professor P. Elliott (London, GB)

Event: EHRA 2022

Congress Presentation

About the speaker

Professor Perry Mark Elliott

University College London, London (United Kingdom of Great Britain & Northern Ireland)

55 presentations

16 followers

4 more presentations in this session

Genetic risk calculators.

Speaker: Doctor R. Tadros (Montreal, CA)

Access

Slides

Video

LQTS: how to use the novel calculator.

Speaker: Doctor H. Tan (Amsterdam, NL)

Access

Slides

Video

ARVC in 2021: do we implant the right patients?

Speaker: Professor P. Lambiase (London, GB)

Access

Slides

Video

Risk calculators in arrhythmias: are they useful? - discussion.

Access

Video

Access the full session

Risk calculators in arrhythmias: are they useful?

Speakers: Professor P. Elliott, Doctor R. Tadros, Doctor H. Tan, Professor P. Lambiase

Access

Video

About the event

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress

HCM: who should get an implantable cardioverter defibrillator in Europe and the US in 2022?

About the speaker

Professor Perry Mark Elliott

4 more presentations in this session

Genetic risk calculators.

LQTS: how to use the novel calculator.

ARVC in 2021: do we implant the right patients?

Risk calculators in arrhythmias: are they useful? - discussion.

Access the full session

Risk calculators in arrhythmias: are they useful?

About the event

EHRA 2022

ESC 365 is supported by